Evidence map›Paper›PMID 32636851›Full record

ReviewFrontiers in immunology2020

Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19).

Ruben Manuel Luciano Colunga Biancatelli, Max Berrill, John D Catravas, Paul E Marik

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04578158 (A Prospective, Randomized, Open-labelled, Controlled Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With Diagnosis of COVID-19.), which is not on this map. Cited by 238 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
238citing papers in PubMed, 6 pooled it
50.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04578158 phase3completednot on this map

A Prospective, Randomized, Open-labelled, Controlled Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With Diagnosis of COVID-19.

TypeinterventionalSponsorLiaquat University of Medical & Health SciencesRan2020 to 2021Enrolled152ConditionsCOVID-19ArmsStandard COVID-19 care, Quercetin Phytosome
3 · Its place in the literature

Who cites it

238 citing papers in PubMed, 6 syntheses or guidelines pooled it, 507 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Bioactive Compounds ofInternational journal of molecular sciences · 2026
    Article
  18. Article
  19. Article
  20. Review

178 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 3 countries.

Ruben Manuel Luciano Colunga BiancatelliDivision of Pulmonary and Critical Care Medicine, Eastern Virginia Medical School, Norfolk, VA, United States.
Max BerrillDepartment of Respiratory Medicine, St. Peter's Hospital, Surrey, United Kingdom.
John D CatravasDivision of Pulmonary and Critical Care Medicine, Eastern Virginia Medical School, Norfolk, VA, United States.
Paul E MarikDivision of Pulmonary and Critical Care Medicine, Eastern Virginia Medical School, Norfolk, VA, United States.
Eastern Virginia Medical School · USPoliclinico Umberto I · ITSt Peter's Hospital · GB

Funding

Antidotes against mustard-induced chronic lung injuryR21ES030528 · NIEHS · OLD DOMINION UNIVERSITY · PI CATRAVAS, JOHN D · 2018 to 2019
$426k
NIEHS NIH HHS R21 ES030528
6 · The paper itself

Abstract

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) represents an emergent global threat which is straining worldwide healthcare capacity. As of May 27th, the disease caused by SARS-CoV-2 (COVID-19) has resulted in more than 340,000 deaths worldwide, with 100,000 deaths in the US alone. It is imperative to study and develop pharmacological treatments suitable for the prevention and treatment of COVID-19. Ascorbic acid is a crucial vitamin necessary for the correct functioning of the immune system. It plays a role in stress response and has shown promising results when administered to the critically ill. Quercetin is a well-known flavonoid whose antiviral properties have been investigated in numerous studies. There is evidence that vitamin C and quercetin co-administration exerts a synergistic antiviral action due to overlapping antiviral and immunomodulatory properties and the capacity of ascorbate to recycle quercetin, increasing its efficacy. Safe, cheap interventions which have a sound biological rationale should be prioritized for experimental use in the current context of a global health pandemic. We present the current evidence for the use of vitamin C and quercetin both for prophylaxis in high-risk populations and for the treatment of COVID-19 patients as an adjunct to promising pharmacological agents such as Remdesivir or convalescent plasma.

Indexed as

AnimalsAntiviral AgentsAscorbic AcidBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentDrug SynergismDrug Therapy, CombinationHumansImmunologic FactorsMicePandemicsPneumonia, ViralPre-Exposure ProphylaxisQuercetinAntiviral AgentsAscorbic AcidImmunologic FactorsQuercetinantiviralCoronavirusCOVID-19flavonoidsimmunonutritionquercetinSARS-Cov-2vitamin C

Identifiers

PMID32636851
PMCPMC7318306
OpenAlexW3035876959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.